Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?

BILICI A., USTAALIOGLU B. B. O. , ERCAN S., ORCUN A., SEKER M., Salepçi T., Gumus M.

doi:10.1007/s00280-010-1480-0

Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?

BILICI A., USTAALIOGLU B. B. O. , ERCAN S., ORCUN A., SEKER M., Salepçi T., et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY, cilt.68, ss.309-316, 2011

Cilt numarası: 68 Konu: 2
Basım Tarihi: 2011
Doi Numarası: 10.1007/s00280-010-1480-0
Dergi Adı: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Sayfa Sayısı: ss.309-316

Özet

M30 and M65 are different circulating fragments of cytokeratin 18. They release during apoptotic cell death, so it is believed that they reflect cell death of epithelial tumors. The aim of this study was to determine the prognostic value of plasma M30 and M65 levels in predicting of survival for patients with advanced gastric cancer compare with healthy controls.